Literature DB >> 1540489

The absorption site of cyclosporin in the human gastrointestinal tract.

J Drewe1, C Beglinger, T Kissel.   

Abstract

1. An emulsion preparation of cyclosporin was administered locally to different parts of the small and large intestine by gavage: to the duodenum (opposite to the papilla of Vater), jejunum (150 cm distal to the teeth), ileum (300 cm distal to the teeth), and to the colon descendens (30 cm proximal to the anus). 2. The bioavailability of cyclosporin after these instillations was compared with that after oral administration of a hard gelatine capsule formulation. 3. Cyclosporin was found to be absorbed predominantly in the small intestine. This may have implications for dosage in patients with reduced absorptive surface area.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540489      PMCID: PMC1381197          DOI: 10.1111/j.1365-2125.1992.tb03998.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

2.  High-fat meals increase the clearance of cyclosporine.

Authors:  S K Gupta; L Z Benet
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

3.  Treatment of refractory ulcerative colitis with cyclosporin enemas.

Authors:  J Brynskov; L Freund; O O Thomsen; C B Andersen; S N Rasmussen; V Binder
Journal:  Lancet       Date:  1989-04-01       Impact factor: 79.321

Review 4.  Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.

Authors:  R Venkataramanan; G J Burckhart; R J Ptachcinski
Journal:  Semin Liver Dis       Date:  1985-11       Impact factor: 6.115

5.  Pediatric liver transplantation: the Dallas experience.

Authors:  W Andrews; B Fyock; S Gray; D Coln; W Hendrickse; J Siegel; B Belknap; A Hogge; M Benser; B Kennard
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

6.  Malabsorption of cyclosporin in renal transplant recipient with Crohn's disease.

Authors:  J D Williams; J R Salaman; P J Griffin; A N Hillis; W Ross; G T Williams
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

7.  The effects and side effects of cyclosporine: relationship to drug pharmacokinetics.

Authors:  P A Keown; C R Stiller; A L Laupacis; W Howson; R Coles; M Stawecki; J Koegler; G Carruthers; N McKenzie; N R Sinclair
Journal:  Transplant Proc       Date:  1982-12       Impact factor: 1.066

8.  Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier.

Authors:  W T Cefalu; W M Pardridge
Journal:  J Neurochem       Date:  1985-12       Impact factor: 5.372

9.  Cyclosporin binding to a protein component of the renal Na(+)-D-glucose cotransporter.

Authors:  K Ziegler; M Frimmer; G Fritzsch; H Koepsell
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

10.  Small-bowel length and the dose of cyclosporine in children after liver transplantation.

Authors:  P F Whitington; J C Emond; S H Whitington; C E Broelsch; A L Baker
Journal:  N Engl J Med       Date:  1990-03-15       Impact factor: 91.245

View more
  23 in total

1.  Once-a-day oral dosing regimen of cyclosporin A: combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates.

Authors:  C K Kim; H J Shin; S G Yang; J H Kim; Y K Oh
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Oral absorption of FK506 in rats.

Authors:  A Kagayama; S Tanimoto; J Fujisaki; A Kaibara; K Ohara; K Iwasaki; Y Hirano; T Hata
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

5.  Prediction of intestinal drug absorption properties by three-dimensional solubility parameters.

Authors:  J Breitkreutz
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

Review 6.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

7.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

8.  Explaining variability in ciclosporin exposure in adult kidney transplant recipients.

Authors:  Rogier R Press; Bart A Ploeger; Jan den Hartigh; T van der Straaten; Hans van Pelt; Meindert Danhof; Hans de Fijter; Henk-Jan Guchelaar
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

9.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.